Last updated on September 8th, 2022 at 09:16 am
List of Top Swiss Based Pharmaceutical Companies which are sorted out based on the total Revenue in the recent year. Roche is the largest Pharmaceutical Company in Switzerland with a Revenue of $ 66 Billion in the last year followed by Novartis and Vifor.
Roche – Largest Pharma company in Swiss: Throughout 125-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas.
List of Top Swiss Based Pharmaceutical Companies
So here is the List of Top Swiss Based Pharmaceutical Companies by total Sales (Revenue).
| S.NO | Description | Total Revenue | Employees | Debt to Equity Ratio | Return on Equity | Stock Symbol |
| 1 | ROCHE | $ 65,980 Million | 101465 | 0.4 | 40.4 | RO |
| 2 | NOVARTIS | $ 51,668 Million | 105794 | 0.6 | 17.3 | NOVN |
| 3 | VIFOR | $ 1,930 Million | 2600 | 0.2 | 5.9 | VIFN |
| 4 | SIEGFRIED | $ 956 Million | 2500 | 0.9 | 13.9 | SFZN |
| 5 | BACHEM | $ 455 Million | 1529 | 0.3 | 21.3 | BANB |
| 6 | BASILEA | $ 144 Million | 150 | -2.9 | BSLN | |
| 7 | IDORSIA | $ 81 Million | 5.5 | -237.9 | IDIA | |
| 8 | COSMO PHARM | $ 74 Million | 265 | 0.5 | -2.8 | COPN |
| 9 | SANTHERA | $ 17 Million | 91 | 5.2 | -1316.2 | SANN |
| 10 | SPEXIS N | $ 16 Million | 52 | -1.6 | -347.9 | SPEX |
| 11 | EVOLVA N | $ 9 Million | 65 | 0.1 | -29.1 | EVE |
| 12 | NEWRON PHARMA N | $ 6 Million | 3.1 | -110.5 | NWRN | |
| 13 | ADDEX N | $ 4 Million | 27 | 0.0 | -89.8 | ADXN |
Novartis – Second largest Swiss Pharma Company
Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, the company use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, the company consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.
Vifor Pharma
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency and nephrology with a focus on rare diseases. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions.
Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.
Bachem
Bachem was founded in 1971 by Peter Grogg as Bachem Feinchemikalien AG with two employees in Liestal near Basel with the focus on peptide synthesis. In 1977, Bachem moved to Bubendorf with eight employees and in 1978 produced peptides for use in medicine under GMP guidelines for the first time. Between 1981 and 1991, Bachem tripled its production capacity, while the number of employees grew to 150. In 1995, the facilities, including the quality control department, were expanded to a total of 168,000 sq. ft. (15,600 m2). The number of employees grew to 190.
Expansion into non-European markets began with the founding of Bachem Bioscience, Inc. in Philadelphia, USA, in 1987. To strengthen its presence in Europe, Bachem opened sales and marketing centers in Germany in 1988 and in France in 1993. In 1996, it acquired the second largest manufacturer of peptides, Bachem California in Torrance, USA, together with its subsidiaries in Germany and the UK.
Bachem goes public on June 18, 1998. The shares are listed on the Swiss Stock Exchange. The Group achieved sales of 96 million CHF and employed 331 people worldwide. In 1999, Bachem acquires Peninsula Laboratories, Inc., based in San Carlos, California, and its subsidiary in England, which is merged with Bachem UK – itself originally a subsidiary of California-based Bachem Inc. in 2000.
The acquisition of Sochinaz SA, a Swiss-based (Vionnaz) specialized manufacturer of active pharmaceutical ingredients in 2001, strengthened Bachem’s expertise and once again expanded its manufacturing capabilities. The headcount of the Group grew at this time to 500 employees and sales reached 141,4 million CHF.
So finally these are the List of Top Swiss Based Pharmaceutical Companies based on the sales in the recent year.
Read More about Top Pharma companies in India.
